The first-line therapy pattern transition of metastatic HER2-positive gastric cancer is shifting. The KEYNOTE-811 study demonstrated that the addition of immunotherapy to the standard treatment of HER2-targeted therapy and chemotherapy showed good results in terms of PFS, especially in subgroup patients with PD-L1 CPS≥1. In the future, the first-line therapy pattern of metastatic HER2-positive gastric cancer will be radically changed based on ongoing randomized controlled clinical trials.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11077284PMC
http://dx.doi.org/10.1002/mco2.545DOI Listing

Publication Analysis

Top Keywords

first-line therapy
12
gastric cancer
12
therapy pattern
8
metastatic her2-positive
8
her2-positive gastric
8
keynote-811 potential
4
potential revise
4
revise first-line
4
therapy
4
therapy metastatic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!